Toni K Choueiri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6798379/publications.pdf

Version: 2024-02-01

1,066	88,444	587 125	515 267
papers	citations	h-index	g-index

1099	1099	1099	63423
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1803-1813.	13.9	4,889
2	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	6.6	3,706
3	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
4	Post-acute COVID-19 syndrome. Nature Medicine, 2021, 27, 601-615.	15.2	3,051
5	Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 2013, 499, 43-49.	13.7	2,839
6	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	13.9	2,677
7	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115.	13.9	1,824
8	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factorâ€“Targeted Agents: Results From a Large, Multicenter Study. Journal of Clinical Oncology, 2009, 27, 5794-5799.	0.8	1,751
9	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2013, 369, 722-731.	13.9	1,648
10	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
11	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 135-145.	13.9	1,040
12	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823.	13.9	1,004
13	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841.	13.9	961
14	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	13.9	956
15	Systemic Therapy for Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2017, 376, 354-366.	13.9	940
16	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	15.2	900
17	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898
18	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	7.7	821

#	Article	IF	Citations
19	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology, The, 2013, 14, 141-148.	5.1	808
20	Marital Status and Survival in Patients With Cancer. Journal of Clinical Oncology, 2013, 31, 3869-3876.	0.8	789
21	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 917-927.	5.1	789
22	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	6.3	778
23	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231.	3.8	746
24	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	7.7	665
25	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	5.1	594
26	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology, 2017, 35, 591-597.	0.8	584
27	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 rgBT /Overlock 10	6.3	529
28	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
29	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	7.7	506
30	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications, 2019, 10, 1617.	5.8	499
31	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
32	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	7.7	482
33	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 804-834.	2.3	443
34	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	9.4	438
35	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell, 2017, 31, 820-832.e3.	7.7	433
36	Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, 181-186.	0.8	401

#	Article	IF	Citations
37	Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. Journal of Clinical Oncology, 2010, 28, 2280-2285.	0.8	400
38	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 385, 683-694.	13.9	394
39	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	0.8	385
40	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2014, 66, 704-710.	0.9	382
41	Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 2359-66.	3.8	377
42	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 127-131.	0.8	373
43	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	1.6	354
44	Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. European Urology, 2014, 66, 42-54.	0.9	349
45	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	2.0	343
46	Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. Journal of Clinical Oncology, 2010, 28, 1850-1855.	0.8	340
47	Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of Oncology, 2019, 30, 970-976.	0.6	329
48	The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. Journal of Urology, 2011, 185, 60-66.	0.2	322
49	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3916-3923.	0.8	316
50	Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology, 2020, 31, 1030-1039.	0.6	316
51	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncology, The, 2018, 19, 405-415.	5.1	305
52	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investigational New Drugs, 2014, 32, 178-187.	1.2	302
53	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncology, The, 2015, 16, 293-300.	5.1	299
54	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports, 2016, 14, 2476-2489.	2.9	298

#	Article	IF	Citations
55	Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 1517-1524.	0.8	291
56	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2Î± Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 867-874.	0.8	290
57	Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics, 2016, 48, 725-732.	9.4	288
58	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine, 2020, 26, 1733-1741.	15.2	282
59	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. European Journal of Cancer, 2018, 94, 115-125.	1.3	280
60	Myocarditis in the Setting of Cancer Therapeutics. Circulation, 2019, 140, 80-91.	1.6	278
61	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncology, The, 2015, 16, 426-435.	5.1	272
62	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. European Urology, 2016, 69, 866-874.	0.9	272
63	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discovery, 2014, 4, 546-553.	7.7	266
64	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell, 2021, 39, 649-661.e5.	7.7	263
65	Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2011, 29, 632-638.	0.8	259
66	Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncology, The, 2009, 10, 967-974.	5.1	257
67	Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. New England Journal of Medicine, 2014, 370, 1769-1770.	13.9	251
68	Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 618-630.	2.3	249
69	PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology, 2014, 25, 2178-2184.	0.6	249
70	Targeting the HIF2â€“VEGF axis in renal cell carcinoma. Nature Medicine, 2020, 26, 1519-1530.	15.2	248
71	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 71-90.	2.3	248
72	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Annals of Oncology, 2015, 26, 812-817.	0.6	246

#	Article	IF	Citations
73	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Annals of Oncology, 2021, 32, 787-800.	0.6	240
74	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	1.6	237
75	ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. European Urology, 2014, 66, 77-84.	0.9	234
76	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5461-5471.	3.2	234
77	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	7.7	230
78	Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR. American Journal of Surgical Pathology, 2006, 30, 1097-1104.	2.1	229
79	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	0.8	229
80	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncology, The, 2018, 19, 451-460.	5.1	228
81	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discovery, 2020, 10, 40-53.	7.7	219
82	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Annals of Oncology, 2020, 31, 1320-1335.	0.6	219
83	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research, 2015, 21, 1071-1077.	3.2	217
84	Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer, 2007, 110, 543-550.	2.0	215
85	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology, 2017, 72, 368-376.	0.9	209
86	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. European Urology, 2014, 65, 577-584.	0.9	207
87	A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 529-541.	0.9	205
88	Lack of reduction in racial disparities in cancerâ€specific mortality over a 20â€year period. Cancer, 2014, 120, 1532-1539.	2.0	204
89	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€term followâ€up of the randomized, openâ€label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	2.0	201
90	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200

#	Article	IF	Citations
91	Kidney Cancer, Version 3.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 151-159.	2.3	198
92	Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 4416-4426.	0.8	197
93	COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell, 2020, 38, 629-646.	7.7	196
94	Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2012, 30, 871-877.	0.8	195
95	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	3.2	193
96	Metastatic nonâ€“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 2013, 119, 2999-3006.	2.0	189
97	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 2016, 34, 3267-3275.	0.8	185
98	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1278-1285.	2.3	185
99	von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Journal of Urology, 2008, 180, 860-866.	0.2	180
100	Beyond conventional immune-checkpoint inhibition â€” novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 2021, 18, 199-214.	12.5	179
101	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology, 2019, 75, 100-110.	0.9	178
102	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 458.	3.4	177
103	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Journal of Clinical Oncology, 2016, 34, 3655-3663.	0.8	174
104	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics, 2020, 52, 790-799.	9.4	174
105	Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. Journal of Clinical Oncology, 2014, 32, 1419-1426.	0.8	169
106	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2012, 30, 507-512.	0.8	168
107	Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncology, 2019, 5, 1631.	3.4	166
108	Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer, 2015, 121, 311-319.	2.0	165

#	Article	IF	Citations
109	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. Clinical Cancer Research, 2011, 17, 5443-5450.	3.2	164
110	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1160-1170.	2.3	163
111	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nature Medicine, 2020, 26, 1041-1043.	15.2	161
112	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
113	Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib. Journal of Clinical Oncology, 2011, 29, 3450-3456.	0.8	155
114	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	3.2	154
115	Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of Oncology, 2013, 24, 1466-1472.	0.6	152
116	Inhibition of hypoxia-inducible factor-2Î± in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nature Medicine, 2021, 27, 802-805.	15.2	151
117	Comparative Analysis of Outcomes and Costs Following Open Radical Cystectomy Versus Robot-Assisted Laparoscopic Radical Cystectomy: Results From the US Nationwide Inpatient Sample. European Urology, 2012, 61, 1239-1244.	0.9	149
118	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology, 2021, 7, 1167.	3.4	149
119	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, 2017, 35, 2993-3001.	0.8	145
120	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	5.8	139
121	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	2.0	138
122	Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical Reviews in Oncology/Hematology, 2011, 77, 163-171.	2.0	136
123	Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology, 2011, 22, 1404-1412.	0.6	135
124	A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Annals of Oncology, 2014, 25, 1603-1608.	0.6	134
125	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 2016, 70, 358-364.	0.9	133
126	Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology, 2006, 17, 1766-1771.	0.6	132

#	Article	IF	Citations
127	Adjuvant Treatment for High-Risk Clear Cell Renal Cancer. JAMA Oncology, 2017, 3, 1249.	3.4	131
128	Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression. Journal of Biological Chemistry, 2015, 290, 8110-8120.	1.6	126
129	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. European Urology, 2011, 60, 684-690.	0.9	125
130	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 581-590.	5.1	124
131	Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer, 2010, 116, 5400-5406.	2.0	123
132	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. European Urology, 2015, 67, 100-110.	0.9	122
133	Vascular endothelial growth factorâ€targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer, 2010, 116, 5219-5225.	2.0	121
134	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Annals of Oncology, 2012, 23, 1549-1555.	0.6	121
135	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology, 2014, 25, 149-154.	0.6	121
136	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	0.8	121
137	QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. British Journal of Cancer, 2015, 112, 296-305.	2.9	120
138	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncology, The, 2018, 19, 1688-1698.	5.1	119
139	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology, 2018, 36, 765-772.	0.8	117
140	Time to prostateâ€specific antigen nadir independently predicts overall survival in patients who have metastatic hormoneâ€sensitive prostate cancer treated with androgenâ€deprivation therapy. Cancer, 2009, 115, 981-987.	2.0	116
141	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 888-898.	5.1	114
142	Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Urology, 2011, 185, 439-444.	0.2	113
143	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncology, The, 2012, 13, 927-935.	5.1	112
144	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. Journal of Clinical Oncology, 2014, 32, 2025-2030.	0.8	112

#	Article	IF	Citations
145	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2015, 94, 228-237.	2.0	111
146	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	0.9	110
147	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.2	109
148	Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 2471-2479.	3.2	109
149	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Journal of Clinical Oncology, 2020, 38, 63-70.	0.8	109
150	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. European Urology, 2017, 72, 557-564.	0.9	108
151	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery, 2020, 10, 1514-1527.	7.7	108
152	Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factorâ€“Signaling Inhibitors. Hypertension, 2010, 56, 1131-1136.	1.3	107
153	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	5.8	106
154	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA - Journal of the American Medical Association, 2015, 314, 2077.	3.8	105
155	Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 1247.	3.4	105
156	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. European Urology, 2013, 63, 717-723.	0.9	104
157	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	0.8	104
158	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Network Open, 2021, 4, e2021869.	2.8	104
159	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	12.5	103
160	Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 672-693.	2.3	103
161	Conditional survival and longâ€term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 2022, 128, 2085-2097.	2.0	103
162	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clinical Cancer Research, 2019, 25, 2458-2470.	3.2	102

#	Article	IF	Citations
163	A Model That Predicts the Probability of Positive Imaging in Prostate Cancer Cases With Biochemical Failure After Initial Definitive Local Therapy. Journal of Urology, 2008, 179, 906-910.	0.2	101
164	Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives. Trends in Cardiovascular Medicine, 2013, 23, 104-113.	2.3	101
165	Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed) Tj ETQq1 1 0.784314 rgBT O Factorâ€"Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. European Urology, 2011, 59, 856-862.	0.9	99
166	Testicular Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 772-799.	2.3	98
167	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	0.8	97
168	Thermal Ablation vs Surgery for Localized Kidney Cancer: a Surveillance, Epidemiology, and End Results (SEER) Database Analysis. Urology, 2011, 78, 93-98.	0.5	95
169	BRAF Mutations in Metanephric Adenoma of the Kidney. European Urology, 2012, 62, 917-922.	0.9	95
170	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	3.4	94
171	Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 6702-6708.	3.2	92
172	Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. European Journal of Cancer, 2012, 48, 1519-1524.	1.3	92
173	Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 960-977.	2.3	90
174	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. European Urology, 2016, 70, 516-521.	0.9	90
175	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€"Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2018, 6, 758-765.	1.6	89
176	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. European Urology, 2018, 73, 71-78.	0.9	87
177	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	0.5	86
178	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
179	696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Annals of Oncology, 2020, 31, S1159.	0.6	86
180	An overview of targeted treatments in cancer. Clinical Therapeutics, 2003, 25, 2121-2137.	1.1	85

#	Article	IF	Citations
181	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	5.8	84
182	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clearâ€cell renal cell carcinoma receiving vascular endothelial growth factorâ€targeted therapy. BJU International, 2010, 106, 772-778.	1.3	81
183	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1285-1291.	0.8	81
184	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
185	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	3.2	80
186	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. European Journal of Cancer, 2015, 51, 2580-2586.	1.3	79
187	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 1606.	3.4	79
188	Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials. Journal of Urology, 2011, 185, 116-120.	0.2	78
189	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2015, 13, e79-e85.	0.9	78
190	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 5218-5226.	3.2	77
191	Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment. Arthritis and Rheumatology, 2016, 68, 556-557.	2.9	77
192	Adjuvant Vascular Endothelial Growth Factorâ€“targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology, 2018, 74, 611-620.	0.9	77
193	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine, 2014, 3, 835-844.	1.3	76
194	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
195	Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. Urology, 2010, 76, 430-434.	0.5	75
196	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 101-101.	0.8	75
197	Progressionâ€free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer, 2011, 117, 2637-2642.	2.0	74
198	Analgesic use and the risk of kidney cancer: A metaâ€analysis of epidemiologic studies. International Journal of Cancer, 2014, 134, 384-396.	2.3	73

#	Article	IF	Citations
199	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	2.3	72
200	Clinical and Genomic Characterization of Lowâ€“Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	0.9	72
201	IL-8 and cancer prognosis on immunotherapy. Nature Medicine, 2020, 26, 650-651.	15.2	72
202	Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 502-535.	2.3	71
203	Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 756-764.	0.4	71
204	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European Urology, 2014, 65, 1086-1092.	0.9	71
205	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. European Urology, 2019, 76, 861-867.	0.9	71
206	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	0.8	70
207	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.2	70
208	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology, 2014, 65, 723-730.	0.9	69
209	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). Journal of Clinical Oncology, 2020, 38, 4240-4248.	0.8	69
210	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Journal of Clinical Oncology, 2021, 39, 3725-3736.	0.8	69
211	Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid Leukemia. Mayo Clinic Proceedings, 2005, 80, 1215-1216.	1.4	68
212	Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma. European Urology, 2014, 66, 502-509.	0.9	68
213	Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practiceâ€based on medical chart review. BJU International, 2010, 105, 1247-1254.	1.3	67
214	Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1411-1416.	0.4	67
215	Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treatment Reviews, 2014, 40, 190-196.	3.4	67
216	Association of androgenâ€deprivation therapy with excess cardiacâ€specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	1.3	66

#	Article	IF	Citations
217	Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 84572-84578.	0.8	66
218	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 119, 663-669.	2.9	66
219	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.	0.9	65
220	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 3615-3623.	0.8	65
221	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2013, 11, 311-315.	0.9	64
222	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British Journal of Cancer, 2014, 110, 1917-1922.	2.9	64
223	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poorâ€risk metastatic renal cell carcinoma. Cancer, 2015, 121, 3435-3443.	2.0	64
224	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2013, 87, 80-89.	2.0	63
225	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	3.2	63
226	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. Journal of the National Cancer Institute, 2015, 107, djv054-djv054.	3.0	63
227	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunology Research, 2016, 4, 820-822.	1.6	63
228	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Preventive Medicine, 2016, 89, 140-145.	1.6	63
229	Cytoreductive nephrectomy in patients with metastatic nonâ€clearâ€cell renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, E67-74.	1.3	62
230	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	0.9	62
231	Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2015, 67, 952-958.	0.9	61
232	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. Journal of Clinical Oncology, 2019, 37, 4513-4513.	0.8	61
233	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Journal of Cancer, 2016, 65, 102-108.	1.3	60
234	Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer. Archives of Internal Medicine, 2011, 171, 1487.	4.3	59

#	Article	IF	Citations
235	Mental health outcomes in elderly men with prostate cancer1Equal contribution.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	0.8	59
236	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	2.6	59
237	The influence of obesity-related factors in the etiology of renal cell carcinomaâ€"A mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	3.9	59
238	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 372-381.	2.6	59
239	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. British Journal of Cancer, 2020, 122, 555-563.	2.9	59
240	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 431-431.	0.8	59
241	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	3.4	58
242	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncology, The, 2022, 23, 172-184.	5.1	58
243	Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941. Journal of Urology, 2007, 178, 1901-1905.	0.2	57
244	Impact of prostateâ€specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgenâ€deprivation therapy. Prostate, 2011, 71, 1189-1197.	1.2	57
245	The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer and Prostatic Diseases, 2014, 17, 273-279.	2.0	57
246	Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188559.	3.3	57
247	Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer, 2006, 107, 2609-2616.	2.0	56
248	Kidney Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 175-182.	2.3	56
249	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research, 2018, 6, 402-408.	1.6	56
250	Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. , 2018, 6, 159.		56
251	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
252	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. Journal of Clinical Oncology, 2017, 35, 4505-4505.	0.8	55

#	Article	IF	Citations
253	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. Journal of Urology, 2016, 195, 277-282.	0.2	54
254	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist, 2017, 22, 286-292.	1.9	54
255	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 118, 1176-1178.	2.9	54
256	Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell, 2020, 38, 769-770.	7.7	54
257	Income inequality and treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e7-18.e13.	0.8	53
258	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. European Urology, 2016, 69, 634-641.	0.9	53
259	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2018, 124, 3677-3683.	2.0	53
260	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	2.0	53
261	Elicitation of health state utilities in metastatic renal cell carcinoma. Current Medical Research and Opinion, 2010, 26, 1091-1096.	0.9	52
262	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. European Urology, 2012, 61, 307-316.	0.9	52
263	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncology, The, 2013, 14, 81-87.	5.1	52
264	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	0.8	52
265	Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology, 2011, 80, 291-300.	2.0	51
266	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer, 2021, 127, 840-849.	2.0	51
267	CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research, 2021, 27, 4025-4035.	3.2	51
268	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU International, 2011, 108, 1279-1283.	1.3	50
269	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research, 2019, 25, 6080-6088.	3.2	50
270	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer, 2020, 135, 203-210.	1.3	50

#	Article	IF	Citations
271	Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Annals of Oncology, 2007, 18, 249-255.	0.6	49
272	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. Journal of Clinical Oncology, 2015, 33, 3431-3438.	0.8	49
273	Radiologic Heterogeneity in Responses to Antiâ€“PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 12-17.	1.6	49
274	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Current Urology Reports, 2017, 18, 15.	1.0	49
275	Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications, 2017, 8, 199.	5.8	49
276	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	3.2	49
277	NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-29.	2.3	48
278	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	1.7	47
279	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
280	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. Journal of Urology, 2020, 204, 1173-1179.	0.2	47
281	Collecting duct carcinoma of the kidney is associated withCDKN2Adeletion andSLCfamily gene up-regulation. Oncotarget, 2016, 7, 29901-29915.	0.8	47
282	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with highâ€risk localized prostate cancer. Cancer, 2012, 118, 4777-4784.	2.0	46
283	Racial Disparities in Prostate Cancerâ€“Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	0.9	46
284	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports, 2016, 6, 27702.	1.6	46
285	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. European Urology, 2018, 73, 452-461.	0.9	46
286	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncology, The, 2018, 19, e317-e326.	5.1	46
287	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. Cancer Cell, 2020, 37, 738-741.	7.7	46
288	Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Current Opinion in Investigational Drugs, 2008, 9, 658-71.	2.3	46

#	Article	IF	Citations
289	Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2013, 19, 316-323.	1.0	45
290	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	1.3	45
291	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research, 2018, 24, 1805-1815.	3.2	45
292	Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Seminars in Arthritis and Rheumatism, 2018, 47, 907-910.	1.6	45
293	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
294	Patterns of Care for Radical Prostatectomy in the United States From 2003 to 2005. Journal of Urology, 2008, 180, 1969-1974.	0.2	44
295	10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study. Oncologist, 2014, 19, 507-514.	1.9	44
296	Complications After Metastasectomy for Renal Cell Carcinomaâ€"A Population-based Assessment. European Urology, 2017, 72, 171-174.	0.9	44
297	Phase I Trials of Anti-ENPP3 Antibodyâ€"Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research, 2018, 24, 4399-4406.	3.2	44
298	Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. Oncogenesis, 2019, 8, 7.	2.1	44
299	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. European Urology Focus, 2019, 5, 474-481.	1.6	44
300	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genetics in Medicine, 2020, 22, 709-718.	1.1	44
301	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology, 2020, 78, 615-623.	0.9	44
302	Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. Nature Clinical Practice Oncology, 2008, 5, 444-454.	4.3	43
303	Adrenocortical carcinoma: The management of metastatic disease. Critical Reviews in Oncology/Hematology, 2014, 92, 123-132.	2.0	43
304	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. European Urology, 2015, 68, 32-39.	0.9	43
305	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. European Urology, 2018, 73, 445-451.	0.9	43
306	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. Journal of Clinical Oncology, 2018, 36, 757-764.	0.8	43

#	Article	IF	Citations
307	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. European Urology, 2019, 75, 552-555.	0.9	43
308	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA Network Open, 2022, 5, e224304.	2.8	43
309	Sunitinibâ€induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer, 2008, 113, 1309-1314.	2.0	42
310	Risk of Bilateral Renal Cell Cancer. Journal of Clinical Oncology, 2009, 27, 3737-3741.	0.8	42
311	Severe Pazopanib-Induced Hepatotoxicity: Clinical and Histologic Course in Two Patients. Journal of Clinical Oncology, 2012, 30, e264-e268.	0.8	42
312	PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond. Cancer Immunology Research, 2014, 2, 1132-1141.	1.6	42
313	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2016, 196, 1090-1095.	0.2	42
314	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals of Oncology, 2017, 28, 1098-1104.	0.6	42
315	Nonâ€“Clear Cell Renal Cell Carcinomas: From Shadow to Light. Journal of Clinical Oncology, 2018, 36, 3624-3631.	0.8	42
316	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 292-303.	5.1	42
317	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1788-1793.	0.8	41
318	<scp>HER2</scp> as a target in invasive urothelial carcinoma. Cancer Medicine, 2015, 4, 844-852.	1.3	41
319	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European Urology, 2015, 68, 506-515.	0.9	41
320	Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta OncolÃ³gica, 2013, 52, 1202-1212.	0.8	40
321	Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria. Cancer, 2014, 120, 711-721.	2.0	40
322	Definition and Validation of â€œFavorable High-Risk Prostate Cancerâ€: Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.4	40
323	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. European Urology Focus, 2016, 2, 204-209.	1.6	40
324	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	0.9	40

#	Article	IF	Citations
325	Variation in the use of active surveillance for lowâ€risk prostate cancer. Cancer, 2018, 124, 55-64.	2.0	40
326	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncology, 2019, 15, 929-941.	1.1	40
327	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genetics in Medicine, 2020, 22, 1366-1373.	1.1	40
328	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 1815.	3.4	40
329	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	2.9	40
330	Haematologic toxicities associated with the addition of bevacizumab in cancer patients. European Journal of Cancer, 2011, 47, 1161-1174.	1.3	39
331	Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer. Drugs, 2013, 73, 1417-1430.	4.9	39
332	Suicide and accidental deaths among patients with nonâ€metastatic prostate cancer. BJU International, 2016, 118, 286-297.	1.3	39
333	Statins and survival outcomes in patients with metastatic renal cell carcinoma. European Journal of Cancer, 2016, 52, 155-162.	1.3	39
334	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	0.9	39
335	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	2.0	39
336	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European Urology, 2021, 79, 334-338.	0.9	39
337	Role of aromatase inhibitors in the treatment of breast cancer. Clinical Therapeutics, 2004, 26, 1199-1214.	1.1	38
338	Recombinant Human Erythropoietin Is Associated with Increased Overall Survival in Patients with Multiple Myeloma. Acta Haematologica, 2007, 117, 162-167.	0.7	38
339	The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients. Current Oncology Reports, 2012, 14, 295-306.	1.8	38
340	RNA-seq Reveals Aurora Kinaseâ€“Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Molecular Cancer Research, 2015, 13, 130-137.	1.5	38
341	Evaluation of diseaseâ€free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trialâ€level metaâ€analysis. Cancer, 2018, 124, 925-933.	2.0	38
342	Rethinking Clinical Trials Reform During the COVID-19 Pandemic. JAMA Oncology, 2020, 6, 1327.	3.4	38

#	Article	IF	Citations
343	Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Annals of Oncology, 2006, 17, 860-865.	0.6	37
344	The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER2 Overexpression and May Help Predict Response to Chemotherapy: A Retrospective Immunohistochemical Study. Breast Journal, 2007, 13, 130-139.	0.4	37
345	Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opinion on Drug Safety, 2011, 10, 645-653.	1.0	37
346	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	2.3	37
347	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2015, 93, 257-276.	2.0	37
348	Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Medicine, 2017, 6, 902-909.	1.3	37
349	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
350	Radiogenomics in renal cell carcinoma. Abdominal Radiology, 2019, 44, 1990-1998.	1.0	37
351	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Network Open, 2020, 3, e201839.	2.8	37
352	Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).. Journal of Clinical Oncology, 2012, 30, 372-372.	0.8	37
353	Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open, 2014, 4, e003921.	0.8	36
354	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 820-824.	2.3	36
355	Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983.	0.9	36
356	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2926-2937.	0.8	36
357	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British Journal of Cancer, 2015, 112, 1190-1198.	2.9	35
358	Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 496.e11-496.e16.	0.8	35
359	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	1.1	35
360	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. Journal of Clinical Oncology, 2017, 35, 4504-4504.	0.8	35

#	Article	IF	Citations
361	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
362	The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma. Seminars in Oncology, 2006, 33, 596-606.	0.8	34
363	Determinants of Performing Radical Prostatectomy Pelvic Lymph Node Dissection and the Number of Lymph Nodes Removed in Elderly Men. Urology, 2011, 77, 402-406.	0.5	34
364	Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2012, 104, 1837-1840.	3.0	34
365	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. PLoS ONE, 2015, 10, e0139267.	1.1	34
366	Asian Americans and prostate cancer: A nationwide population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e7-233.e15.	0.8	34
367	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 352-359.	0.9	34
368	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 724-732.	0.9	34
369	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer, 2018, 118, 1434-1441.	2.9	34
370	Impact of postoperative prostateâ€specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer, 2010, 116, 1887-1892.	2.0	33
371	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer, 2011, 47, 2706-2714.	1.3	33
372	Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 335.	0.4	33
373	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2015, 94, 136-145.	2.0	33
374	Determinants of cancer screening in Asian-Americans. Cancer Causes and Control, 2016, 27, 989-998.	0.8	33
375	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer, 2018, 118, 1238-1242.	2.9	33
376	Survey of the Impact of COVID-19 on Oncologistsâ€™ Decision Making in Cancer. JCO Global Oncology, 2020, 6, 1248-1257.	0.8	33
377	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. Cancer Science, 2020, 111, 907-923.	1.7	33
378	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemporary Clinical Trials, 2021, 108, 106482.	0.8	33

#	Article	IF	Citations
379	Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.. Journal of Clinical Oncology, 2016, 34, 4507-4507.	0.8	33
380	Phase I/II study of the oral HIF-2 Î± inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, 611-611.	0.8	33
381	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. European Urology, 2022, 81, 266-271.	0.9	33
382	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitorâ€“Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. Journal of Clinical Oncology, 2022, 40, 1929-1938.	0.8	33
383	Treatment selection for patients with metastatic renal cell carcinoma. Cancer, 2009, 115, 2327-2333.	2.0	32
384	Nonâ€“Clear Cell Renal Cancer: Features and Medical Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 659-665.	2.3	32
385	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. Journal of Urology, 2016, 195, 913-918.	0.2	32
386	Comprehensive Analysis of Survival Outcomes in Nonâ€“Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clinical Genitourinary Cancer, 2017, 15, 652-660.e1.	0.9	32
387	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. European Journal of Surgical Oncology, 2018, 44, 1439-1445.	0.5	32
388	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330.	2.8	32
389	Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. British Journal of Cancer, 2012, 107, 1009-1016.	2.9	31
390	ABO blood group and risk of renal cell cancer. Cancer Epidemiology, 2012, 36, 528-532.	0.8	31
391	Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU International, 2013, 112, E273-80.	1.3	31
392	Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Annals of Oncology, 2013, 24, 2092-2097.	0.6	31
393	Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. British Journal of Cancer, 2013, 108, 2478-2484.	2.9	31
394	A nomogram including baseline prognostic factors to estimate the activity of secondâ€line therapy for advanced urothelial carcinoma. BJU International, 2014, 113, E137-43.	1.3	31
395	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2017, 198, 817-823.	0.2	31
396	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.2	31

#	Article	IF	Citations
397	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2018, 200, 573-581.	0.2	31
398	Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. Thyroid, 2018, 28, 437-444.	2.4	31
399	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2019, 2, 643-648.	2.6	31
400	Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. European Urology Oncology, 2021, 4, 893-903.	2.6	31
401	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. Journal of Urology, 2019, 201, 735-741.	0.2	31
402	Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer, 2011, 117, 4846-4854.	2.0	30
403	Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Annals of Oncology, 2013, 24, 2927-2928.	0.6	30
404	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clinical Genitourinary Cancer, 2021, 19, e92-e99.	0.9	30
405	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.. Journal of Clinical Oncology, 2014, 32, 5012-5012.	0.8	30
406	Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Review of Anticancer Therapy, 2009, 9, 373-379.	1.1	29
407	A phase 2, singleâ€arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer, 2014, 120, 1647-1655.	2.0	29
408	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. European Urology, 2014, 66, 1125-1132.	0.9	29
409	Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. Thyroid, 2018, 28, 445-453.	2.4	29
410	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcomeâ€"Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2020, 3, 530-539.	2.6	29
411	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Science Translational Medicine, 2021, 13, .	5.8	29
412	Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.. Journal of Clinical Oncology, 2013, 31, 4514-4514.	0.8	29
413	A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate) Tj ETQq1 1 0.784314 rgBT /Overlock		
414	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clinical Cancer Research, 2022, 28, 928-938.	3.2	29

#	Article	IF	Citations
415	Phenoxodiol: Isoflavone analog with antineoplastic activity. Current Oncology Reports, 2006, 8, 104-107.	1.8	28
416	An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU International, 2008, 101, 712-715.	1.3	28
417	Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*. Current Medical Research and Opinion, 2009, 25, 2081-2090.	0.9	28
418	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 2018, 119, 707-712.	2.9	28
419	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. Journal of Clinical Oncology, 2017, 35, 4507-4507.	0.8	28
420	Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer. Urologic Clinics of North America, 2007, 34, 137-148.	0.8	27
421	Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer, 2012, 118, 797-803.	2.0	27
422	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 130-137.	0.9	27
423	Risk factors and model for predicting toxicityâ€related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factorâ€“targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2016, 122, 411-419.	2.0	27
424	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	2.0	27
425	Sex specific associations in genome wide association analysis of renal cell carcinoma. European Journal of Human Genetics, 2019, 27, 1589-1598.	1.4	27
426	Response of Renal Cell Carcinoma Pancreatic Metastasis to Sunitinib Treatment: A Retrospective Analysis. Journal of Urology, 2009, 181, 2470-2475.	0.2	26
427	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clinical Genitourinary Cancer, 2014, 12, 354-358.	0.9	26
428	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research, 2019, 25, 5202-5211.	3.2	26
429	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
430	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 187-196.	1.8	26
431	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 102-111.	2.6	26
432	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncology, The, 2022, 23, 899-909.	5.1	26

#	Article	IF	Citations
433	A Case of Adult Metastatic Xp11 Translocation Renal Cell Carcinoma Treated Successfully With Sunitinib. Clinical Genitourinary Cancer, 2009, 7, E93-E94.	0.9	25
434	Which Patients With Undetectable PSA Levels 5 Years After Radical Prostatectomy Are Still at Risk of Recurrence?â€"Implications for a Risk-adapted Follow-up Strategy. Urology, 2010, 76, 1201-1205.	0.5	25
435	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e127-e131.	0.9	25
436	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. Annals of Oncology, 2015, 26, 2392-2398.	0.6	25
437	Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open, 2021, 6, 100101.	2.0	25
438	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research, 2021, 27, 6687-6695.	3.2	25
439	Systemic Therapy for Metastatic Nonâ€"Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions. Hematology/Oncology Clinics of North America, 2011, 25, 853-869.	0.9	24
440	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 17.e9-17.e18.	0.8	24
441	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factorâ€"Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research, 2018, 24, 4081-4088.	3.2	24
442	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. Oncologist, 2019, 24, 202-210.	1.9	24
443	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. European Journal of Cancer, 2020, 127, 118-122.	1.3	24
444	A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. Oncologist, 2021, 26, 182-e361.	1.9	24
445	Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2020, 38, 617-617.	0.8	24
446	Reduced Penile Size and Treatment Regret inÂMen With Recurrent Prostate Cancer After Surgery, Radiotherapy Plus Androgen Deprivation, or Radiotherapy Alone. Urology, 2013, 81, 130-135.	0.5	23
447	Association Between Older Age and Increasing Gleason Score. Clinical Genitourinary Cancer, 2015, 13, 525-530.e3.	0.9	23
448	Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology, 2019, 26, 175-179.	0.9	23
449	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. , 2021, 9, e001506.		23
450	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1042-1044.	7.7	23

#	Article	IF	Citations
451	Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.. Journal of Clinical Oncology, 2017, 35, 4523-4523.	0.8	23
452	The impact of COVID-19 on cancer care and oncology clinical research: an expertsâ€™ perspective. ESMO Open, 2022, 7, 100339.	2.0	23
453	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncology, The, 2022, 23, 768-780.	5.1	23
454	Differential expression of caveolin-1 in renal neoplasms. Cancer, 2007, 110, 776-782.	2.0	22
455	Androgenâ€suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU International, 2010, 106, 979-985.	1.3	22
456	Future Directions and Targeted Therapies in Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 361-376.	0.9	22
457	Treatment of Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 888-890.	13.9	22
458	Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 2016, 117, E20-8.	1.3	22
459	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist, 2019, 24, 1497-1501.	1.9	22
460	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
461	A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investigational New Drugs, 2021, 39, 1019-1027.	1.2	22
462	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer, 2021, 151, 115-125.	1.3	22
463	Cabozantinib realâ€world effectiveness in the firstâ€through fourthâ€line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine, 2021, 10, 1212-1221.	1.3	22
464	Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.. Journal of Clinical Oncology, 2022, 40, 290-290.	0.8	22
465	Review: Updates on novel therapies for metastatic renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2010, 2, 209-219.	1.4	21
466	Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality. Journal of Urology, 2012, 187, 2068-2073.	0.2	21
467	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factorâ€targeted therapy. Cancer, 2012, 118, 365-370.	2.0	21
468	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 2014, 5, 352-358.	0.5	21

#	Article	IF	Citations
469	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	0.6	21
470	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. Urology, 2015, 85, 343-350.	0.5	21
471	RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factorâ€"Targeted Therapy. American Journal of Roentgenology, 2015, 204, W282-W288.	1.0	21
472	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	0.8	21
473	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	0.8	21
474	711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. Annals of Oncology, 2020, 31, S559-S560.	0.6	21
475	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 773.	3.4	21
476	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. Journal of Clinical Oncology, 2019, 37, 548-548.	0.8	21
477	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1049-1058.	2.3	21
478	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	3.2	21
479	Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2003, 3, 823-829.	1.1	20
480	Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncology, 2008, 4, 85-92.	1.1	20
481	Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy, 2011, 11, 997-1009.	1.4	20
482	Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Aging Male, 2012, 15, 34-41.	0.9	20
483	Factors Associated with the Adoption of Minimally Invasive Radical Prostatectomy in the United States. Journal of Urology, 2012, 188, 775-780.	0.2	20
484	Impact of Response to Prior Chemotherapy inÂPatients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications forÂTrial Design. Clinical Genitourinary Cancer, 2013, 11, 495-500.	0.9	20
485	MET as a Target in Papillary Renal Cell Carcinoma. Clinical Cancer Research, 2014, 20, 3361-3363.	3.2	20
486	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology, 2014, 9, 195-204.	1.7	20

#	Article	IF	Citations
487	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. European Urology, 2018, 73, 262-270.	0.9	20
488	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	0.7	20
489	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	2.0	20
490	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	2.6	20
491	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. European Urology, 2021, 79, 665-673.	0.9	20
492	Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma. PLoS ONE, 2014, 9, e116101.	1.1	20
493	The impact of Medicare eligibility on cancer screening behaviors. Preventive Medicine, 2016, 85, 47-52.	1.6	19
494	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 120-126.	2.0	19
495	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
496	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer, 2020, 126, 1-10.	1.3	19
497	LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. Annals of Oncology, 2020, 31, S1201-S1202.	0.6	19
498	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
499	Patientâ€reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU International, 2020, 126, 73-82.	1.3	19
500	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigatorâ€™s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 410-410.	0.8	19
501	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.	0.8	19
502	Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 848-855.	0.8	18
503	Use of Surveillance Imaging Following Treatment of Small Renal Masses. Journal of Urology, 2013, 190, 1680-1685.	0.2	18
504	Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. British Journal of Cancer, 2014, 110, 1433-1437.	2.9	18

#	Article	IF	Citations
505	NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1629-1649.	2.3	18
506	Validation and genomic interrogation of the <scp>MET</scp> variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer, 2016, 122, 402-410.	2.0	18
507	Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 221-229.	0.9	18
508	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9â€“10 Prostate Cancer. European Urology, 2019, 75, 35-41.	0.9	18
509	Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 464-470.	1.0	18
510	Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Annals of Internal Medicine, 2020, 173, 368-374.	2.0	18
511	Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, 4504-4504.	0.8	18
512	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. Journal of Clinical Oncology, 2018, 36, 4518-4518.	0.8	18
513	Results from a phase I expansion cohort of the first-in-class oral HIF-2Î± inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.. Journal of Clinical Oncology, 2019, 37, 558-558.	0.8	18
514	Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. European Journal of Cancer, 2012, 48, 1495-1502.	1.3	17
515	Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT	1.0	17
516	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
517	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	0.8	17
518	Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Annals of Oncology, 2018, 29, 386-391.	0.6	17
519	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	0.9	17
520	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	2.0	17
521	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. European Journal of Cancer, 2021, 145, 1-10.	1.3	17
522	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. Journal of Clinical Oncology, 2015, 33, 3009-3009.	0.8	17

#	Article	IF	Citations
523	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 4501-4501.	0.8	17
524	Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. Nature Communications, 2021, 12, 7304.	5.8	17
525	CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. British Journal of Cancer, 2022, 126, 797-803.	2.9	17
526	VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives. Current Clinical Pharmacology, 2011, 6, 164-168.	0.2	16
527	Clinical Treatment Decisions for Advanced Renal Cell Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 694-697.	2.3	16
528	Precision medicine for metastatic renal cell carcinoma11Disclosures: Guru Sonpavde, MD: Research support from Novartis, Pfizer, and speaker or advisory board for Novartis, Pfizer, and GSK. Toni K. Choueiri, MD: Research support from Pfizer. Advisory board: Pfizer, Novartis, Aveo, GSK, Bayer/Onyx, and Genentech. No speakers bureau.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 5-15.	0.8	16
529	Incidence and determinants of 1-month mortality after cancer-directed surgery. Annals of Oncology, 2015, 26, 399-406.	0.6	16
530	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factorâ€targeted therapies. Cancer, 2016, 122, 2389-2398.	2.0	16
531	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with â‰¥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	0.5	16
532	Immunotherapy in the Elderly. European Urology Focus, 2017, 3, 403-412.	1.6	16
533	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Reports, 2021, 34, 108926.	2.9	16
534	Assessing population diversity in phase <scp>III</scp> trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. International Journal of Cancer, 2021, 149, 1455-1462.	2.3	16
535	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4599-TPS4599.	0.8	16
536	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS ONE, 2015, 10, e0124711.	1.1	16
537	Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer. Oncologist, 2011, 16, 1484-1486.	1.9	15
538	Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 497-506.	0.6	15
539	Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. Clinical Cancer Research, 2021, 27, 2087-2099.	3.2	15
540	Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.. Journal of Clinical Oncology, 2014, 32, 4505-4505.	0.8	15

#	Article	IF	Citations
541	Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).. Journal of Clinical Oncology, 2015, 33, 2503-2503.	0.8	15
542	Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.. Journal of Clinical Oncology, 2017, 35, 3036-3036.	0.8	15
543	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. Journal of Clinical Oncology, 2017, 35, TPS4594-TPS4594.	0.8	15
544	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2018, 36, 581-581.	0.8	15
545	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. Journal of Clinical Oncology, 2020, 38, 608-608.	0.8	15
546	Anti-CAIX BBÎ¶ CAR4/8 TÂcells exhibit superior efficacy in a ccRCC mouse model. Molecular Therapy - Oncolytics, 2022, 24, 385-399.	2.0	15
547	COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). ESMO Open, 2022, 7, 100499.	2.0	15
548	RET protein expression in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 900-905.	0.8	14
549	The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. British Journal of Cancer, 2013, 109, 2548-2553.	2.9	14
550	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate, 2015, 75, 1677-1681.	1.2	14
551	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 538-545.	0.8	14
552	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
553	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal CellÂCarcinoma. Clinical Genitourinary Cancer, 2017, 15, 403-410.e2.	0.9	14
554	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, e961-e967.	0.9	14
555	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genetics, 2018, 14, e1007679.	1.5	14
556	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs, 2020, 38, 1807-1814.	1.2	14
557	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. , 2020, 8, e000371.		14
558	Care without a compass: Including patients with cancer in COVID-19 studies. Cancer Cell, 2021, 39, 895-896.	7.7	14

#	Article	IF	Citations
559	Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. New England Journal of Medicine, 2021, 385, 287-287.	13.9	14
560	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2012, 30, 387-387.	0.8	14
561	Non-clear cell renal cell carcinoma, part 2: therapy. Clinical Advances in Hematology and Oncology, 2015, 13, 383-91.	0.3	14
562	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer, 2022, 171, 124-132.	1.3	14
563	Sunitinib-Induced Pseudoprogression After Whole-Brain Radiotherapy for Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2010, 28, e433-e435.	0.8	13
564	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e19-330.e25.	0.8	13
565	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.2	13
566	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer, 2017, 1, 41-47.	0.2	13
567	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	0.6	13
568	Qualityâ€adjusted survival with firstâ€line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). Cancer, 2020, 126, 5311-5318.	2.0	13
569	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 5598-5608.	3.2	13
570	Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, 364-364.	0.8	13
571	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. Journal of Clinical Oncology, 2014, 32, 467-467.	0.8	13
572	Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 544-544.	0.8	13
573	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. Ca-A Cancer Journal for Clinicians, 2022, 72, 454-489.	157.7	13
574	Everolimus- and Temsirolimus-Associated Enteritis: Report of Three Cases. Journal of Clinical Oncology, 2011, 29, e404-e406.	0.8	12
575	Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Medical Research Methodology, 2014, 14, 138.	1.4	12
576	Patient Eligibility and Trial Design for the Salvage Therapy ofÂAdvanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 395-398.	0.9	12

#	Article	IF	Citations
577	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. European Urology Focus, 2016, 2, 633-639.	1.6	12
578	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology, 2017, 71, 970-978.	0.9	12
579	The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. Clinical Genitourinary Cancer, 2018, 16, e327-e333.	0.9	12
580	Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patientsâ€™ Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737â€“46. European Urology, 2018, 74, e139-e140.	0.9	12
581	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	1.2	12
582	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, 19, e306-e312.	0.9	12
583	Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 607-607.	0.8	12
584	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	3.2	12
585	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2022, 40, 3633-3641.	0.8	12
586	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4045-4055.	3.2	12
587	Acquired Activated Protein C Resistance in Myeloma Patients with Venous Thromboembolic Events. British Journal of Haematology, 2003, 123, 959-959.	1.2	11
588	Comorbidity, body mass index, and age and the risk of nonprostateâ€cancerâ€specific mortality after a postradiation prostateâ€specific antigen recurrence. Cancer, 2010, 116, 610-615.	2.0	11
589	Renal Cell Carcinoma. Hematology/Oncology Clinics of North America, 2011, 25, xiii-xiv.	0.9	11
590	Risk of All-Cause and Prostate Cancerâ€“Specific Mortality After Brachytherapy in Men With Small Prostate Size. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1318-1322.	0.4	11
591	CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Annals of Oncology, 2016, 27, vi566.	0.6	11
592	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 304-313.e6.	0.9	11
593	Recurrence in renal cell carcinoma: the work is not done. Nature Reviews Urology, 2016, 13, 246-247.	1.9	11
594	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	0.9	11

#	Article	IF	Citations
595	Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion. JCO Precision Oncology, 2017, 1, 1-5.	1.5	11
596	Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. Journal of Global Oncology, 2018, 4, 1-8.	0.5	11
597	Use of Preventive Health Services Among Cancer Survivors in the U.S.. American Journal of Preventive Medicine, 2018, 55, 830-838.	1.6	11
598	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e1060-e1068.	0.9	11
599	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 425-435.e4.	0.9	11
600	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 690-696.	1.9	11
601	Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. JAMA Oncology, 2020, 6, 133.	3.4	11
602	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). Annals of Oncology, 2020, 31, S1202-S1203.	0.6	11
603	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer, 2020, 18, e598-e609.	0.9	11
604	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 187-197.	1.8	11
605	Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.. Journal of Clinical Oncology, 2013, 31, 351-351.	0.8	11
606	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. Journal of Clinical Oncology, 2015, 33, 4500-4500.	0.8	11
607	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. Journal of Clinical Oncology, 2016, 34, 4509-4509.	0.8	11
608	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2016, 34, TPS4576-TPS4576.	0.8	11
609	Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).. Journal of Clinical Oncology, 2019, 37, 4518-4518.	0.8	11
610	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. Journal of Clinical Oncology, 2019, 37, 4583-4583.	0.8	11
611	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS684-TPS684.	0.8	11
612	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research, 2022, 28, 738-747.	3.2	11

#	Article	IF	Citations
613	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 756-763.	0.8	10
614	Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. Annals of Oncology, 2011, 22, 245-247.	0.6	10
615	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer, 2015, 13, 150-155.	0.9	10
616	Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design. Clinical Genitourinary Cancer, 2015, 13, 71-79.	0.9	10
617	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26.		10
618	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	2.3	10
619	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREÂ® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.2	10
620	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.	0.2	10
621	709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. Annals of Oncology, 2020, 31, S558.	0.6	10
622	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) â€“ an International mRCC Database Consortium (IMDC) analysis. Journal of Geriatric Oncology, 2021, 12, 820-826.	0.5	10
623	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer, 2021, 21, 904.	1.1	10
624	Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer, 2021, 160, 78-83.	0.9	10
625	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 499-499.	0.8	10
626	Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab.. Journal of Clinical Oncology, 2016, 34, 514-514.	0.8	10
627	Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).. Journal of Clinical Oncology, 2017, 35, 482-482.	0.8	10
628	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. Journal of Clinical Oncology, 2018, 36, 413-413.	0.8	10
629	Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).. Journal of Clinical Oncology, 2018, 36, 579-579.	0.8	10
630	The Evolving Landscape of Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 299-302.	1.8	10

#	Article	IF	Citations
631	TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.. Journal of Clinical Oncology, 2022, 40, TPS405-TPS405.	0.8	10
632	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	2.8	10
633	Optimizing recent advances in metastatic renal cell carcinoma. Current Oncology Reports, 2009, 11, 218-226.	1.8	9
634	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	1.1	9
635	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clinical Genitourinary Cancer, 2014, 12, 262-269.	0.9	9
636	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2014, 12, 335-340.	0.9	9
637	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 503.e7-503.e15.	0.8	9
638	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. British Journal of Cancer, 2016, 115, 12-19.	2.9	9
639	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.4	9
640	Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology, 2018, 29, viii311.	0.6	9
641	Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology, 2019, 76, 852-860.	0.9	9
642	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer, 2019, 17, 65-71.	0.9	9
643	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 4807-4813.	3.2	9
644	Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 157, 50-58.	1.3	9
645	Clinical activity and safetyÂof anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastaticÂrenal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2012, 30, 4505-4505.	0.8	9
646	Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.. Journal of Clinical Oncology, 2014, 32, 5027-5027.	0.8	9
647	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2014, 32, 396-396.	0.8	9
648	Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS4580-TPS4580.	0.8	9

#	Article	IF	Citations
649	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 545-545.	0.8	9
650	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 435-435.	0.8	9
651	Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 566-566.	0.8	9
652	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open, 2022, 5, e2142046.	2.8	9
653	First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. Oncologist, 2022, 27, 125-134.	1.9	9
654	Non-clear cell renal cell carcinoma, part 1: histology. Clinical Advances in Hematology and Oncology, 2015, 13, 308-13.	0.3	9
655	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clinical Cancer Research, 2022, 28, 748-755.	3.2	9
656	The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discovery, 2022, 12, 1620-1624.	7.7	9
657	An evaluation of the â€˜weekend effectâ€™ in patients admitted with metastatic prostate cancer. BJU International, 2015, 116, 911-919.	1.3	8
658	Metastatic renal cell carcinoma: Contending with a sea change in therapy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 507-508.	0.8	8
659	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2015, 95, 251-263.	2.0	8
660	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	2.0	8
661	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. Oncologist, 2021, 26, e905-e906.	1.9	8
662	A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.. Journal of Clinical Oncology, 2012, 30, 355-355.	0.8	8
663	A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).. Journal of Clinical Oncology, 2017, 35, 436-436.	0.8	8
664	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS706-TPS706.	0.8	8
665	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. Journal of Clinical Oncology, 2022, 40, 352-352.	0.8	8
666	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. Open Forum Infectious Diseases, 2022, 9, ofac037.	0.4	8

#	Article	IF	Citations
667	Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. European Urology, 2022, 82, 247-251.	0.9	8
668	Factors Associated with Outcome in Patients with Advanced Renal Cell Carcinoma in the Era of Antiangiogenic Agents. Clinical Genitourinary Cancer, 2008, 6, 15-20.	0.9	7
669	New therapies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2011, 12, 2069-2074.	0.9	7
670	Renal-cell carcinoma: a step closer to a new classification. Lancet Oncology, The, 2013, 14, 105-107.	5.1	7
671	Diagnosis of Renal Cell Carcinoma. Surgical Pathology Clinics, 2015, 8, 657-662.	0.7	7
672	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	0.9	7
673	Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy. Clinical Genitourinary Cancer, 2017, 15, 396-402.	0.9	7
674	Dissecting the immunogenomic biology of cancer for biomarker development. Nature Reviews Clinical Oncology, 2021, 18, 133-134.	12.5	7
675	Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.. Journal of Clinical Oncology, 2021, 39, 310-310.	0.8	7
676	Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2014, 32, 4503-4503.	0.8	7
677	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. Journal of Clinical Oncology, 2014, 32, 398-398.	0.8	7
678	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, TPS4571-TPS4571.	0.8	7
679	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 426-426.	0.8	7
680	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	0.8	7
681	Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.. Journal of Clinical Oncology, 2018, 36, 582-582.	0.8	7
682	CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS682-TPS682.	0.8	7
683	Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. European Journal of Medical Genetics, 2021, 64, 104359.	0.7	7
684	FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. BJUI Compass, 2022, 3, 169-172.	0.7	7

#	Article	IF	Citations
685	Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clinical Genitourinary Cancer, 2022, 20, 301-306.	0.9	7
686	Risk Assessment in Small Renal Masses. Urologic Clinics of North America, 2017, 44, 189-202.	0.8	6
687	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus, 2020, 6, 37-40.	1.6	6
688	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). Oncologist, 2021, 26, 560-e1103.	1.9	6
689	OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Global Oncology, 2021, 7, 455-463.	0.8	6
690	Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	6
691	cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).. Journal of Clinical Oncology, 2015, 33, 487-487.	0.8	6
692	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2016, 34, 4524-4524.	0.8	6
693	Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.. Journal of Clinical Oncology, 2016, 34, 4558-4558.	0.8	6
694	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. Journal of Clinical Oncology, 2017, 35, 4530-4530.	0.8	6
695	Pembrolizumab (pembro) versus investigatorâ€™s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.. Journal of Clinical Oncology, 2018, 36, 4521-4521.	0.8	6
696	Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1261-1283.	0.9	5
697	Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy, 2013, 12, 415-421.	0.2	5
698	Incomplete Cross-Resistance Between Taxanes forÂAdvanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clinical Genitourinary Cancer, 2015, 13, 250-256.	0.9	5
699	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. JAMA Oncology, 2016, 2, 543.	3.4	5
700	Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database. Journal of Global Oncology, 2018, 4, 1-14.	0.5	5
701	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 341-348.	0.9	5
702	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2021, 39, TPS4596-TPS4596.	0.8	5

#	Article	IF	Citations
703	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. Journal of Clinical Oncology, 2014, 32, 4585-4585.	0.8	5
704	PD-L1 expression in non-clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 424-424.	0.8	5
705	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.. Journal of Clinical Oncology, 2015, 33, 4508-4508.	0.8	5
706	A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 2506-2506.	0.8	5
707	Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.. Journal of Clinical Oncology, 2016, 34, 73-73.	0.8	5
708	A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, TPS4595-TPS4595.	0.8	5
709	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. Journal of Clinical Oncology, 2018, 36, TPS712-TPS712.	0.8	5
710	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2019, 37, 103-103.	0.8	5
711	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4514-4514.	0.8	5
712	PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. Journal of Clinical Oncology, 2019, 37, TPS4596-TPS4596.	0.8	5
713	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. Journal of Clinical Oncology, 2020, 38, 5063-5063.	0.8	5
714	Why shouldn't we use warfarin alone to treat acute venous thrombosis?. Cleveland Clinic Journal of Medicine, 2002, 69, 546-548.	0.6	5
715	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 684-684.	0.8	5
716	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precision Oncology, 2022, 6, e2100448.	1.5	5
717	Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. American Journal of Medicine, 2002, 113, 700-701.	0.6	4
718	The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. Nature Clinical Practice Oncology, 2008, 5, 698-699.	4.3	4
719	Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncology, The, 2009, 10, 740.	5.1	4
720	Data on Medicare eligibility and cancer screening utilization. Data in Brief, 2016, 7, 679-681.	0.5	4

#	Article	IF	Citations
721	Advances in treatment â€" jostling for pole position. Nature Reviews Clinical Oncology, 2017, 14, 82-84.	12.5	4
722	Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial. Annals of Oncology, 2017, 28, v623.	0.6	4
723	The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 443-450.e1.	0.9	4
724	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology, 2020, 6, 293-306.	0.8	4
725	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e17-130.e24.	0.8	4
726	Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2021, 39, 472-472.	0.8	4
727	Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.. Journal of Clinical Oncology, 2021, 39, 4548-4548.	0.8	4
728	A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2021, 39, TPS4594-TPS4594.	0.8	4
729	Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.. Journal of Clinical Oncology, 2021, 39, 4514-4514.	0.8	4
730	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. Journal of Urology, 2019, 201, 728-734.	0.2	4
731	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2013, 31, 398-398.	0.8	4
732	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2014, 32, 4576-4576.	0.8	4
733	Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.. Journal of Clinical Oncology, 2014, 32, 416-416.	0.8	4
734	Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 3013-3013.	0.8	4
735	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 4557-4557.	0.8	4
736	Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2017, 35, 3016-3016.	0.8	4
737	Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.. Journal of Clinical Oncology, 2018, 36, 4516-4516.	0.8	4
738	Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).. Journal of Clinical Oncology, 2018, 36, 4556-4556.	0.8	4

#	Article	IF	Citations
739	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, TPS42-TPS42.	0.8	4
740	Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, 639-639.	0.8	4
741	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2019, 37, 4568-4568.	0.8	4
742	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2019, 37, 584-584.	0.8	4
743	Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 652-652.	0.8	4
744	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).. Journal of Clinical Oncology, 2019, 37, 653-653.	0.8	4
745	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. Journal of Clinical Oncology, 2020, 38, e19321-e19321.	0.8	4
746	Radiologic response (RR) by MRI in patients (pts) with muscle-invasive urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, 283-283.	0.8	4
747	Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury. Kidney360, 2021, 2, 205-214.	0.9	4
748	Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007. European Urology Supplements, 2008, 7, 494-507.	0.1	3
749	Sunitinib in RCCâ€"expanded access equals expanded benefit?. Nature Reviews Clinical Oncology, 2009, 6, 679-680.	12.5	3
750	Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. Journal of Clinical Oncology, 2016, 34, 777-779.	0.8	3
751	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Nonâ€"Lymph Node Distant Metastasis. Clinical Genitourinary Cancer, 2017, 15, e1089-e1094.	0.9	3
752	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. Annals of Oncology, 2018, 29, viii315.	0.6	3
753	Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. Annals of Oncology, 2018, 29, viii308.	0.6	3
754	Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigatorâ€™s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. Annals of Oncology, 2018, 29, viii320-viii321.	0.6	3
755	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e350-e359.	0.9	3
756	Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. Cancer Discovery, 2021, 11, 1330-1335.	7.7	3

#	Article	IF	Citations
757	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 166, 103463.	2.0	3
758	Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET).. Journal of Clinical Oncology, 2012, 30, 352-352.	0.8	3
759	A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.. Journal of Clinical Oncology, 2012, 30, 353-353.	0.8	3
760	Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.. Journal of Clinical Oncology, 2014, 32, 4510-4510.	0.8	3
761	The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.. Journal of Clinical Oncology, 2014, 32, TPS4593-TPS4593.	0.8	3
762	Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. Journal of Clinical Oncology, 2014, 32, 437-437.	0.8	3
763	Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT).. Journal of Clinical Oncology, 2014, 32, 470-470.	0.8	3
764	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2015, 33, 430-430.	0.8	3
765	Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset.. Journal of Clinical Oncology, 2017, 35, 4517-4517.	0.8	3
766	Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.. Journal of Clinical Oncology, 2018, 36, 230-230.	0.8	3
767	Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4515-4515.	0.8	3
768	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS4597-TPS4597.	0.8	3
769	Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2019, 37, 550-550.	0.8	3
770	Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101.. Journal of Clinical Oncology, 2020, 38, 690-690.	0.8	3
771	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 715-715.	0.8	3
772	Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials.. Journal of Clinical Oncology, 2013, 31, 353-353.	0.8	3
773	Abstract 4541:METgene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor. , 2018, , .		3
774	Risk of bleeding not increased by sorafenib or sunitinib â€“ Authors' reply. Lancet Oncology, The, 2010, 11, 113.	5.1	2

#	Article	IF	Citations
775	Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2013, 16, 266-270.	2.0	2
776	The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1168-1170.	2.3	2
777	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy forÂUrothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 185-192.	0.9	2
778	MP34-11 NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY. Journal of Urology, 2017, 197, .	0.2	2
779	MP86-17 THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA. Journal of Urology, 2017, 197, .	0.2	2
780	Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma. Kidney Cancer, 2018, 2, 37-46.	0.2	2
781	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	1.5	2
782	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. Kidney Cancer, 2019, 3, 241-251.	0.2	2
783	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 29-39.	0.2	2
784	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e9-735.e15.	0.8	2
785	Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).. Journal of Clinical Oncology, 2021, 39, 4578-4578.	0.8	2
786	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemporary Clinical Trials, 2021, 108, 106481.	0.8	2
787	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.2	2
788	JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncology, The, 2018, 19, 5-7.	5.1	2
789	Abstract 2976: Comprehensive Pan-Genomic characterization of adrenocortical carcinoma. , 2015, , .		2
790	Abstract A18: Genomic and neoantigen evolution and resistance to immune checkpoint blockade in metastatic renal cell carcinoma. , 2017, , .		2
791	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2012, 30, 4525-4525.	0.8	2
792	A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, TPS4686-TPS4686.	0.8	2

#	Article	IF	Citations
793	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 301-301.	0.8	2
794	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2013, 31, 394-394.	0.8	2
795	PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2014, 32, 4552-4552.	0.8	2
796	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology, 2014, 32, 353-353.	0.8	2
797	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. Journal of Clinical Oncology, 2015, 33, 4559-4559.	0.8	2
798	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. Journal of Clinical Oncology, 2015, 33, 405-405.	0.8	2
799	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 408-408.	0.8	2
800	Can pelvic lymph node dissection be omitted in intermediate-risk prostate cancer patients? A SEER-based comparative study using inverse-probability-of-treatment weighting.. Journal of Clinical Oncology, 2015, 33, 95-95.	0.8	2
801	Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study.. Journal of Clinical Oncology, 2016, 34, 2565-2565.	0.8	2
802	Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2016, 34, 4540-4540.	0.8	2
803	Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 570-570.	0.8	2
804	Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial.. Journal of Clinical Oncology, 2017, 35, 4579-4579.	0.8	2
805	Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden.. Journal of Clinical Oncology, 2017, 35, 4582-4582.	0.8	2
806	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. Journal of Clinical Oncology, 2017, 35, 346-346.	0.8	2
807	ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).. Journal of Clinical Oncology, 2018, 36, e18690-e18690.	0.8	2
808	Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.. Journal of Clinical Oncology, 2018, 36, TPS4600-TPS4600.	0.8	2
809	The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement.. Journal of Clinical Oncology, 2018, 36, 279-279.	0.8	2
810	Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2018, 36, 453-453.	0.8	2

#	Article	IF	Citations
811	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2018, 36, 615-615.	0.8	2
812	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. Journal of Clinical Oncology, 2018, 36, 619-619.	0.8	2
813	Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects.. Journal of Clinical Oncology, 2019, 37, 1528-1528.	0.8	2
814	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. Journal of Clinical Oncology, 2020, 38, 5010-5010.	0.8	2
815	Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.. Journal of Clinical Oncology, 2020, 38, 728-728.	0.8	2
816	Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2014, 32, 409-409.	0.8	2
817	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. Journal of Medical Internet Research, 2019, 21, e12044.	2.1	2
818	Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.. Journal of Clinical Oncology, 2020, 38, 698-698.	0.8	2
819	OUP accepted manuscript. Oncologist, 2022, , .	1.9	2
820	First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 317-317.	0.8	2
821	Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results.. Journal of Clinical Oncology, 2022, 40, 323-323.	0.8	2
822	Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 308-308.	0.8	2
823	Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 334-334.	0.8	2
824	Impact of MET status on treatment outcomes in papillary renal cell carcinoma: AÂpooled analysis of historical data. European Journal of Cancer, 2022, 170, 158-168.	1.3	2
825	Metastatic renal cell carcinoma: A guide to therapy based on current evidence. Urology Annals, 2009, 1, 9.	0.3	1
826	¹¹Câ€METHIONINE POSITRONâ€EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PETâ€CT) IN EVALUATING METASTATIC TRANSITIONAL CELL CARCINOMA RESPONSE TO SUNITINIB THERAPY. BJU International, 2010, 106, 1249-1250.	1.3	1
827	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. Journal of Clinical Oncology, 2014, 32, 4171-4172.	0.8	1
828	Racial Disparities in the Management of African American Men With Intermediate- to High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S446.	0.4	1

#	Article	IF	Citations
829	MP13-13 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN VS. MINIMALLY INVASIVE RADICAL NEPHROURETERECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES. Journal of Urology, 2014, 191, .	0.2	1
830	Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. , 2015, 3, .		1
831	PD04-05 TRENDS OF METASTASECTOMY FOR METASTATIC RENAL CELL CARCINOMA AND THEIR IMPACT ON OVERALL SURVIVAL. Journal of Urology, 2016, 195, .	0.2	1
832	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 494-498.	0.9	1
833	A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). Annals of Oncology, 2016, 27, vi280.	0.6	1
834	Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). Annals of Oncology, 2016, 27, vi285.	0.6	1
835	Reply to B. Rini et al and S. Buti et al. Journal of Clinical Oncology, 2017, 35, 1859-1860.	0.8	1
836	Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From aÂPooled Clinical Trials Database. Clinical Genitourinary Cancer, 2018, 16, 13-20.e3.	0.9	1
837	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262â€“70. European Urology, 2018, 73, e100-e101.	0.9	1
838	PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. Annals of Oncology, 2018, 29, viii726.	0.6	1
839	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e15-400.e22.	0.8	1
840	Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).. Journal of Clinical Oncology, 2021, 39, TPS4592-TPS4592.	0.8	1
841	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2021, 39, 4554-4554.	0.8	1
842	A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).. Journal of Clinical Oncology, 2021, 39, TPS4593-TPS4593.	0.8	1
843	Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study. , 2019, , .		1
844	FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.. Journal of Clinical Oncology, 2012, 30, 4577-4577.	0.8	1
845	Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. Journal of Clinical Oncology, 2012, 30, 451-451.	0.8	1
846	Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate.. Journal of Clinical Oncology, 2013, 31, 161-161.	0.8	1

#	Article	IF	Citations
847	First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2013, 31, 430-430.	0.8	1
848	CGH array and matching gene expression profiling for identification of distinct molecular variants among type II papillary renal cell carcinomas.. Journal of Clinical Oncology, 2014, 32, 4527-4527.	0.8	1
849	Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report.. Journal of Clinical Oncology, 2014, 32, 334-334.	0.8	1
850	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology, 2014, 32, 336-336.	0.8	1
851	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 395-395.	0.8	1
852	ABO blood group and risk of lethal prostate cancer.. Journal of Clinical Oncology, 2014, 32, 69-69.	0.8	1
853	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. Journal of Clinical Oncology, 2015, 33, 4519-4519.	0.8	1
854	Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification.. Journal of Clinical Oncology, 2015, 33, 4564-4564.	0.8	1
855	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. Journal of Clinical Oncology, 2015, 33, 311-311.	0.8	1
856	miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel.. Journal of Clinical Oncology, 2015, 33, 364-364.	0.8	1
857	Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 404-404.	0.8	1
858	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 422-422.	0.8	1
859	Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.. Journal of Clinical Oncology, 2015, 33, 433-433.	0.8	1
860	Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium.. Journal of Clinical Oncology, 2015, 33, 464-464.	0.8	1
861	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 4506-4506.	0.8	1
862	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2016, 34, 4570-4570.	0.8	1
863	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. Journal of Clinical Oncology, 2016, 34, e23221-e23221.	0.8	1
864	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. Journal of Clinical Oncology, 2016, 34, 501-501.	0.8	1

#	Article	IF	Citations
865	Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis.. Journal of Clinical Oncology, 2017, 35, 4572-4572.	0.8	1
866	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 4573-4573.	0.8	1
867	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. Journal of Clinical Oncology, 2017, 35, 4585-4585.	0.8	1
868	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2018, 36, 451-451.	0.8	1
869	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 626-626.	0.8	1
870	CD73 expression in primary and metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, 643-643.	0.8	1
871	Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, 645-645.	0.8	1
872	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2018, 36, TPS710-TPS710.	0.8	1
873	Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2012, 30, 349-349.	0.8	1
874	Analgesic useÂand the risk of renal cell carcinoma (RCC): Results from a large up-to-date meta-analysis.. Journal of Clinical Oncology, 2012, 30, 395-395.	0.8	1
875	Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC).. Journal of Clinical Oncology, 2013, 31, 23-23.	0.8	1
876	Metastatic nonâ€“clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. Journal of Clinical Oncology, 2013, 31, 396-396.	0.8	1
877	Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.. Journal of Clinical Oncology, 2013, 31, 347-347.	0.8	1
878	PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.. Journal of Clinical Oncology, 2014, 32, 4526-4526.	0.8	1
879	Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations. , 2014, , .		1
880	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, e15578-e15578.	0.8	1
881	Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group.. Journal of Clinical Oncology, 2015, 33, 4521-4521.	0.8	1
882	The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.. Journal of Clinical Oncology, 2016, 34, 552-552.	0.8	1

#	Article	IF	Citations
883	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 503-503.	0.8	1
884	Abstract 3159: Identification of circulating tumor cells from renal cell carcinoma patients by a multi-parameter flow cytometry assay. , 2016, , .		1
885	Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4570-4570.	0.8	1
886	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4578-4578.	0.8	1
887	Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. Journal of Clinical Oncology, 2017, 35, 11546-11546.	0.8	1
888	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2018, 36, 634-634.	0.8	1
889	Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.. Journal of Clinical Oncology, 2018, 36, e17027-e17027.	0.8	1
890	Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.. Journal of Clinical Oncology, 2018, 36, 3036-3036.	0.8	1
891	Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2019, 37, 3052-3052.	0.8	1
892	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. Journal of Clinical Oncology, 2019, 37, 4577-4577.	0.8	1
893	Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.. Journal of Clinical Oncology, 2020, 38, 5077-5077.	0.8	1
894	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. Journal of Clinical Oncology, 2020, 38, 740-740.	0.8	1
895	Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. European Urology Oncology, 2022, 5, 719-721.	2.6	1
896	Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2022, , .	1.6	1
897	Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.. Journal of Clinical Oncology, 2022, 40, 343-343.	0.8	1
898	Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 310-310.	0.8	1
899	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.. Journal of Clinical Oncology, 2022, 40, 281-281.	0.8	1
900	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2022, 40, 549-549.	0.8	1

#	Article	IF	Citations
901	PROSTATE-SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY AND THE RISK OF DEATH. Journal of Urology, 2009, 181, 577.	0.2	0
902	Reply to D.R. Minor. Journal of Clinical Oncology, 2010, 28, e620-e620.	0.8	0
903	491 TIME TRENDS IN THE UTILIZATION OF HIGHER-COST TREATMENTS FOR PROSTATE CANCER, 2002-2007. Journal of Urology, 2010, 183, .	0.2	0
904	Reply to impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer, 2011, 117, 656-656.	2.0	0
905	Androgen Deprivation Therapy for Prostate Cancer and Cardiovascular Deathâ€"Reply. JAMA - Journal of the American Medical Association, 2012, 307, .	3.8	0
906	132 COST-EFFECTIVENESS ANALYSIS OF PERCUTANEOUS RENAL MASS BIOPSY TO GUIDE THE SURGICAL MANAGEMENT OF SMALL RENAL MASSES. Journal of Urology, 2012, 187, .	0.2	0
907	1389 COMPARATIVE EFFECTIVENESS AND COSTS OF ROBOTIC-ASSISTED LAPAROSCOPIC VERSUS OPEN RADICAL CYSTECTOMY. Journal of Urology, 2012, 187, .	0.2	0
908	MP36-02 VALIDATION AND GENOMIC INTERROGATION OF THE MET VARIANT RS11762213 AS A PREDICTOR OF ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2014, 191, .	0.2	0
909	MP13-14 THE IMPACT OF SURGEON VOLUME ON THE MORBIDITY AND COSTS OF NEPHROURETERECTOMY IN THE UNITED STATES: AÂCONTEMPORARY POPULATION-BASED ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
910	MP63-17 TRENDS OF ACUTE KIDNEY INJURY AFTER RADICAL ORÂPARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA. Journal of Urology, 2015, 193, .	0.2	0
911	MP73-11 ANDROGEN DEPRIVATION THERAPY AND INCREASED NON-CANCER MORTALITY IN PROSTATE CANCER PATIENTS: ANALYSIS OF THE NUMBER NEEDED TO TREAT. Journal of Urology, 2015, 193, .	0.2	0
912	MP50-07 THE ASSOCIATION BETWEEN OBESITY AND INCIDENCE OF TOTAL AND FATAL RENAL CELL CARCINOMA IN TWO PROSPECTIVE COHORTS. Journal of Urology, 2015, 193, .	0.2	0
913	MP60-01 PREVALENCE OF NON-RECOMMENDED SCREENING FOR PROSTATE CANCER AND BREAST CANCER IN THE UNITED STATES. Journal of Urology, 2015, 193, .	0.2	0
914	MP77-12 CONTEMPORARY PATTERNS OF SELF-REPORTED PSA SCREENING IN U.S. VETERANS. Journal of Urology, 2015, 193, .	0.2	0
915	Gleason 5 + 3 = 8 Prostate Cancer: Much More like Gleason 9?. International Journal of Radiation Oncology Biology Physics, 2015, 93, E232-E233.	0.4	0
916	Evaluation of the novel â€œtrial within a trialâ€•design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Annals of Oncology, 2016, 27, vi284.	0.6	0
917	MP73-20 ANALGESIC USE AND RISK OF RENAL CELL CANCER: RESULTS FROM TWO PROSPECTIVE COHORT STUDIES. Journal of Urology, 2016, 195, .	0.2	0
918	MP03-15 TRENDS IN TREATMENT STRATEGIES FOR METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2016, 195, .	0.2	0

#	Article	IF	Citations
919	PD04-06 CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: AN ANALYSIS OF THE NATIONAL CANCER DATA BASE. Journal of Urology, 2016, 195, .	0.2	0
920	Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC). Annals of Oncology, 2016, 27, vi271.	0.6	0
921	Pembrolizumab in patients with Bacillus Calmette GuÃ©rin (BCG)-unresponsive, high-risk nonâ€“muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study. Annals of Oncology, 2016, 27, vi294.	0.6	0
922	MP25-08 DETERMINANTS OF PROSTATE CANCER SCREENING IN ASIAN AMERICANS. Journal of Urology, 2016, 195, .	0.2	0
923	PD37-01 CONTEMPORARY TRENDS IN TREATMENT PATTERNS FORÂMENÂDIAGNOSED WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0
924	MP21-05 TEMPORAL TRENDS IN PROSTATE CANCER RISK GROUP STRATIFICATION FOLLOWING THE 2008 UNITED STATES PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS. Journal of Urology, 2016, 195, .	0.2	0
925	Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. European Urology, 2016, 70, 42-44.	0.9	0
926	Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. European Urology, 2016, 69, 92-93.	0.9	0
927	Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970â€“8. European Urology, 2017, 71, e177-e178.	0.9	0
928	PD62-12 COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR LOCALIZED MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. Journal of Urology, 2017, 197, .	0.2	0
929	In Reply. Oncologist, 2017, 22, 1561-1561.	1.9	0
930	MP22-18 CONTEMPORARY INCIDENCE AND EPIDEMIOLOGIC TRENDS OF BRAIN METASTASES AT RENAL CELL CARCINOMA DIAGNOSIS. Journal of Urology, 2017, 197, .	0.2	0
931	PD28-06 VARIATION IN THE USE OF ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.2	0
932	PD57-03 ASSESSMENT OF THE ECOLOGICAL ASSOCIATION BETWEEN TOBACCO SMOKING EXPOSURE AND BLADDER CANCER INCIDENCE OVER THE PAST HALF-CENTURY IN THE UNITED STATES. Journal of Urology, 2017, 197, .	0.2	0
933	PD10-10 RACIAL DISPARITIES IN DELIVERING DEFINITIVE THERAPY FOR INTERMEDIATE-HIGH RISK LOCALIZED PROSTATE CANCER: THE IMPACT OF FACILITY FEATURES AND SOCIOECONOMIC CHARACTERISTICS. Journal of Urology, 2017, 197, .	0.2	0
934	MP34-19 EFFECT OF HISTOLOGICAL VARIANTS ON THE OUTCOMES OF RADICAL CYSTECTOMY FOR NON-METASTATIC MUSCLE-INVASIVE URINARY BLADDER CANCER. Journal of Urology, 2017, 197, .	0.2	0
935	MP53-18 EFFICACY OF LOCAL TREATMENT IN PROSTATE CANCER PATIENTS WITH CLINICALLY PELVIC LYMPH NODE-POSITIVE DISEASE AT INITIAL DIAGNOSIS. Journal of Urology, 2017, 197, .	0.2	0
936	PD67-09 COMPARATIVE EFFECTIVNESS OF ROBOT-ASSISTED VS. OPEN RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.2	0

#	Article	IF	Citations
937	PD06-01 CLOVIZ: CLINICAL OUTCOMES VISUALIZATION OF IMDC CRITERIA IN METASTATIC RENAL CELL CARCINOMA FOR PATIENT-CENTERED DECISION MAKING. Journal of Urology, 2017, 197, .	0.2	0
938	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC). Annals of Oncology, 2017, 28, v314-v315.	0.6	0
939	Reply to C. Buttigliero et al and B. Biswas et al. Journal of Clinical Oncology, 2017, 35, 1266-1267.	0.8	0
940	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermannsâ€™ Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262â€“70.. European Urology, 2018, 73, e96-e97.	0.9	0
941	Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusionâ€“Positive Metastatic Urothelial Carcinoma. JCO Precision Oncology, 2018, 2, 1-6.	1.5	0
942	Safety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma. Annals of Oncology, 2019, 30, v384-v385.	0.6	0
943	Does CARMENA mark the end of cytoreductive nephrectomy for metastatic renal cell carcinoma?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 525-528.	0.8	0
944	744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC). Annals of Oncology, 2020, 31, S577-S578.	0.6	0
945	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2021, 39, 354-354.	0.8	0
946	Improving tumor mutational burden calibration in non-European patients.. Journal of Clinical Oncology, 2021, 39, 1559-1559.	0.8	0
947	Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study.. Journal of Clinical Oncology, 2021, 39, 4529-4529.	0.8	0
948	Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naÃ¯ve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.. Journal of Clinical Oncology, 2021, 39, 6567-6567.	0.8	0
949	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.. Journal of Clinical Oncology, 2021, 39, 10536-10536.	0.8	0
950	The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).. Journal of Clinical Oncology, 2021, 39, 4552-4552.	0.8	0
951	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2021, 39, 4547-4547.	0.8	0
952	Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2021, 39, 4583-4583.	0.8	0
953	Automated identification of immune related adverse events in oncology patients using machine learning.. Journal of Clinical Oncology, 2021, 39, 1551-1551.	0.8	0
954	B2B: Kidney Cancer Summary. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, S19-S28.	0.2	0

#	Article	IF	Citations
955	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. JCO Clinical Cancer Informatics, 2021, 5, 912-920.	1.0	0
956	HLA-A*03 is a Predictive Biomarker of Poor Response to Immune Checkpoint Blockade in Cancer. SSRN Electronic Journal, 0, , .	0.4	0
957	Cancer of the Genitourinary Tract. , 2010, , 233-277.		0
958	Emerging and Novel Therapeutic Targets in Renal Cancer. Emerging Cancer Therapeutics, 2011, 2, 145-156.	0.1	0
959	Management of Biochemical Recurrence After Localized Treatment for Prostate Cancer. , 2012, , 347-359.		0
960	Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2012, 30, 358-358.	0.8	0
961	Assessment of a cell-line-derived HIF1Î± gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib.. Journal of Clinical Oncology, 2012, 30, 408-408.	0.8	0
962	ABO blood group and risk of renal cell cancer.. Journal of Clinical Oncology, 2012, 30, 371-371.	0.8	0
963	Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone.. Journal of Clinical Oncology, 2012, 30, 38-38.	0.8	0
964	Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine.. Journal of Clinical Oncology, 2012, 30, e15007-e15007.	0.8	0
965	Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2012, 30, e21016-e21016.	0.8	0
966	Sequential Targeted Therapy Following Pazopanib (PZ) in Patients (PTS) with Metastatic Renal Cell Cancer (MRCC): Efficacy and Toxicity. Annals of Oncology, 2012, 23, ix278.	0.6	0
967	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. Journal of Clinical Oncology, 2013, 31, 278-278.	0.8	0
968	Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis.. Journal of Clinical Oncology, 2014, 32, 432-432.	0.8	0
969	Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies.. Journal of Clinical Oncology, 2014, 32, 330-330.	0.8	0
970	Patient risk factors and pegfilgrastim use in cabazitaxel-treated prostate cancer pateints in an academic setting.. Journal of Clinical Oncology, 2014, 32, 224-224.	0.8	0
971	Deep sequencing of sarcomatoid renal cell carcinoma (sRCC) and identification of aurora kinases and mTOR as potential therapeutic targets.. Journal of Clinical Oncology, 2014, 32, 411-411.	0.8	0
972	Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is).. Journal of Clinical Oncology, 2014, 32, 9639-9639.	0.8	0

#	Article	IF	Citations
973	The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. Journal of Clinical Oncology, 2014, 32, 5091-5091.	0.8	0
974	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. Journal of Clinical Oncology, 2014, 32, 4514-4514.	0.8	0
975	Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials.. Journal of Clinical Oncology, 2014, 32, e15558-e15558.	0.8	0
976	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2014, 32, e13547-e13547.	0.8	0
977	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2014, 32, e13502-e13502.	0.8	0
978	A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 4570-4570.	0.8	0
979	Abstract LB-279: Nonsteroidal anti-inflammatory drug (NSAID) use and risk of lethal renal cell carcinoma. , 2014, , .		0
980	Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma. , 2015, , 555-567.		0
981	The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts.. Journal of Clinical Oncology, 2015, 33, 414-414.	0.8	0
982	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. Journal of Clinical Oncology, 2015, 33, 32-32.	0.8	0
983	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).. Journal of Clinical Oncology, 2015, 33, 365-365.	0.8	0
984	Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 435-435.	0.8	0
985	Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.. Journal of Clinical Oncology, 2015, 33, 456-456.	0.8	0
986	Genomic landscape of high-grade T1 micropapillary bladder tumors.. Journal of Clinical Oncology, 2015, 33, 299-299.	0.8	0
987	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2015, 33, 351-351.	0.8	0
988	Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation.. Journal of Clinical Oncology, 2015, 33, 406-406.	0.8	0
989	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. Journal of Clinical Oncology, 2015, 33, 369-369.	0.8	0
990	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. Journal of Clinical Oncology, 2015, 33, 34-34.	0.8	0

#	Article	IF	Citations
991	Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients.. Journal of Clinical Oncology, 2015, 33, 4530-4530.	0.8	0
992	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2015, 33, 4527-4527.	0.8	0
993	Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy.. Journal of Clinical Oncology, 2015, 33, e15518-e15518.	0.8	0
994	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. Journal of Clinical Oncology, 2015, 33, e15520-e15520.	0.8	0
995	Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.. Journal of Clinical Oncology, 2015, 33, 4520-4520.	0.8	0
996	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. Journal of Clinical Oncology, 2015, 33, 4560-4560.	0.8	0
997	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials.. Journal of Clinical Oncology, 2015, 33, e15583-e15583.	0.8	0
998	Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2015, 33, e15519-e15519.	0.8	0
999	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States.. Journal of Clinical Oncology, 2015, 33, e17528-e17528.	0.8	0
1000	Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations. , 2015, , .		0
1001	Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC). , 2015, , .		0
1002	Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies.. Journal of Clinical Oncology, 2016, 34, 363-363.	0.8	0
1003	Analgesic use and risk of renal cell cancer: Results from two prospective cohort studies.. Journal of Clinical Oncology, 2016, 34, 588-588.	0.8	0
1004	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 54-54.	0.8	0
1005	Assessment of metastasectomy complications in renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 619-619.	0.8	0
1006	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report.. Journal of Clinical Oncology, 2016, 34, 450-450.	0.8	0
1007	Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC).. Journal of Clinical Oncology, 2016, 34, 431-431.	0.8	0
1008	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2016, 34, 386-386.	0.8	0

#	Article	IF	Citations
1009	Characterization of mutational load in patients with advanced urothelial cancer.. Journal of Clinical Oncology, 2016, 34, 460-460.	0.8	0
1010	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2016, 34, 616-616.	0.8	0
1011	The impact of weight change during treatment with targeted therapy in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 557-557.	0.8	0
1012	Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival.. Journal of Clinical Oncology, 2016, 34, 620-620.	0.8	0
1013	Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.. Journal of Clinical Oncology, 2016, 34, 534-534.	0.8	0
1014	Impact of metformin on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. Journal of Clinical Oncology, 2016, 34, 531-531.	0.8	0
1015	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.. Journal of Clinical Oncology, 2016, 34, 33-33.	0.8	0
1016	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2016, 34, 442-442.	0.8	0
1017	The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population.. Journal of Clinical Oncology, 2016, 34, 304-304.	0.8	0
1018	Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. Journal of Clinical Oncology, 2016, 34, 4554-4554.	0.8	0
1019	Virtual consults: A paradigm shift for second opinions in oncology care.. Journal of Clinical Oncology, 2016, 34, e18049-e18049.	0.8	0
1020	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. Journal of Clinical Oncology, 2016, 34, 4510-4510.	0.8	0
1021	Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers.. Journal of Clinical Oncology, 2016, 34, 4573-4573.	0.8	0
1022	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. Journal of Clinical Oncology, 2016, 34, 4535-4535.	0.8	0
1023	Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.. Journal of Clinical Oncology, 2016, 34, 3068-3068.	0.8	0
1024	Fixed tissue ChIP-seq (FiT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles.. Journal of Clinical Oncology, 2016, 34, 4541-4541.	0.8	0
1025	Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. Journal of Clinical Oncology, 2017, 35, 4583-4583.	0.8	0
1026	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2017, 35, e16065-e16065.	0.8	0

#	Article	IF	Citations
1027	Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2017, 35, 4580-4580.	0.8	0
1028	Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.. Journal of Clinical Oncology, 2017, 35, e16012-e16012.	0.8	0
1029	Abstract CT090: A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors. , 2017, , .		0
1030	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. Journal of Clinical Oncology, 2018, 36, 679-679.	0.8	0
1031	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 78-78.	0.8	0
1032	Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer.. Journal of Clinical Oncology, 2018, 36, 23-23.	0.8	0
1033	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	0
1034	FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians.. Journal of Clinical Oncology, 2018, 36, 465-465.	0.8	0
1035	The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. Journal of Clinical Oncology, 2018, 36, 492-492.	0.8	0
1036	Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer.. Journal of Clinical Oncology, 2018, 36, 59-59.	0.8	0
1037	Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. Journal of Clinical Oncology, 2018, 36, 629-629.	0.8	0
1038	Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.. Journal of Clinical Oncology, 2018, 36, 4539-4539.	0.8	0
1039	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	0.8	0
1040	Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. Journal of Clinical Oncology, 2018, 36, e17041-e17041.	0.8	0
1041	Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, e16554-e16554.	0.8	0
1042	Comprehensive genomic characterization of urothelial carcinomas.. Journal of Clinical Oncology, 2018, 36, 4527-4527.	0.8	0
1043	Abstract 4585: Development of multi-marker capture and analysis of circulating tumor cells in renal cell carcinoma. , 2018, , .		0
1044	Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 66-66.	0.8	0

#	Article	IF	Citations
1045	Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2019, 37, 664-664.	0.8	0
1046	Hyperprogressive disease on immune checkpoint therapy in advanced solid malignancies: A systematic review.. Journal of Clinical Oncology, 2019, 37, 154-154.	0.8	0
1047	Germline alterations in urothelial carcinoma (UC) patients with family history of UC.. Journal of Clinical Oncology, 2019, 37, 474-474.	0.8	0
1048	Cell-free DNA analysis in renal cell carcinoma: Comparison with tumor sequencing and correlation with response to therapy.. Journal of Clinical Oncology, 2019, 37, 655-655.	0.8	0
1049	Genomic profiling of variant urinary tract tumor histologies.. Journal of Clinical Oncology, 2019, 37, 450-450.	0.8	0
1050	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2019, 37, 454-454.	0.8	0
1051	Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).. Journal of Clinical Oncology, 2019, 37, 4571-4571.	0.8	0
1052	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2019, 37, 4582-4582.	0.8	0
1053	Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.. Journal of Clinical Oncology, 2019, 37, 4578-4578.	0.8	0
1054	Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers. , 2019, , .		0
1055	Abstract 2351: AXL and c-MET cross-talk in the regulation of PD-L1 expression on renal cancer cells. , 2019, , .		0
1056	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. Journal of Clinical Oncology, 2020, 38, 5070-5070.	0.8	0
1057	Detection of urothelial carcinoma using plasma cell-free methylated DNA.. Journal of Clinical Oncology, 2020, 38, 5046-5046.	0.8	0
1058	Ethnicity-Specific Variation in the Germline Landscape of Renal Cell Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
1059	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. Acta OncolÃ³gica, 2022, 61, 52-57.	0.8	0
1060	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. Journal of Clinical Oncology, 2022, 40, 569-569.	0.8	0
1061	Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI).. Journal of Clinical Oncology, 2022, 40, 381-381.	0.8	0
1062	Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.. Journal of Clinical Oncology, 2022, 40, 390-390.	0.8	0

#	Article	IF	Citations
1063	Abstract SY25-02: Widespread germline-somatic regulatory differences in renal cell carcinoma prioritize risk mechanisms. , 2019, , .		0
1064	Patient-reported outcomes: what really matters to patients? â€“ Authors' reply. Lancet Oncology, The, 2022, 23, e199.	5.1	0
1065	Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2022, 20, .	0.1	0
1066	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. Clinical Drug Investigation, 0, , .	1.1	0